SCHEMBL3598118

SCHEMBL3598118

CN(CCNC(=O)Cn1ccc2cccc([N+](=O)[O-])c21)C1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
MAPT P10636 4/20 0.38
TP53 P04637 1/20 0.38
GAA P10253 2/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KDM4E B2RXH2 5/20 0.37
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
BCHE P06276 2/20 0.36
ACHE P22303 2/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3591244 0.85 TSHR (0.42) ALDH1A1MAPTTP53GAATSHR
SCHEMBL3585618 0.85 MAPT (0.40) ALDH1A1MAPTTP53GAATSHR
SCHEMBL14397294 0.85 MAPT (0.40) ALDH1A1MAPTTP53GAATSHR
SCHEMBL3586421 0.85 TSHR (0.41) ALDH1A1MAPTTP53GAATSHR
SCHEMBL3598033 0.83 HTT (0.44) ALDH1A1MAPTTP53GAATSHR
SCHEMBL3597285 0.82 MAPT (0.46) ALDH1A1MAPTTP53GAATSHR
SCHEMBL3598121 0.82 POLB (0.41) ALDH1A1MAPTTP53TSHRMAPK1
SCHEMBL3594706 0.81 GAA (0.42) ALDH1A1MAPTTP53GAATSHR
SCHEMBL3595020 0.80 HSD17B10 (0.52) ALDH1A1MAPTTP53GAATSHR
SCHEMBL3589650 0.80 TSHR (0.41) ALDH1A1MAPTTP53GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 ALDH1A1 662/4885MAPT 2809/4885TP53 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.